Rosa & Co. announces research agreement with Sanofi
The agreement is designed to provide greater access to the extensive depth and breadth of Rosa's expertise and foster enhanced adoption of the PhysioPD platform
Rosa & Co., a drug development advisory firm with expertise in drug-disease modelling and simulation, has announced the initiation of a multi-year research agreement with Sanofi Global R&D to provide Rosa's market-leading PhysioPD services to worldwide Sanofi affiliates. The systematic and long-term collaboration with Rosa provides Sanofi with a competitive research and development advantage across a number of therapeutic areas.
The agreement is designed to provide greater access to the extensive depth and breadth of Rosa's expertise and foster enhanced adoption of the PhysioPD platform development approach throughout Sanofi's entire R&D pipeline.
Rosa's agreement with Sanofi further extends the company’s presence as the global market leader in the quantitative systems pharmacology field. It also reinforces the value that PhysioPD research platforms deliver through greater scientific insight and more informed drug discovery and development decisions.
‘We are honoured that our research agreement with Sanofi is the first that we can announce publicly. It demonstrates their commitment to be a market leader in the use of PhysioPD to achieve the scientific and drug development benefits delivered by PhysioPD research. It also demonstrates the significant value that PhysioPD research can deliver to R&D portfolios,’ said Dr Ron Beaver, Founder, Chairman and CEO, Rosa & Co.
